Compare SGA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGA | BOLD |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3M | 57.5M |
| IPO Year | 1994 | 2024 |
| Metric | SGA | BOLD |
|---|---|---|
| Price | $9.11 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 20.5K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $8.24 | $0.96 |
| 52 Week High | $13.81 | $2.79 |
| Indicator | SGA | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 76.94 |
| Support Level | $8.24 | $1.08 |
| Resistance Level | $9.46 | $2.79 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 83.64 | 79.21 |
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.